Corteva Inc (CTVA) (Q2 2026) Earnings Call Highlights: Strong First-Half Performance and Raised ...

This article first appeared on GuruFocus.

Release Date: July 31, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Strong first-half performance with net sales up 4%, operating EBITDA up 10%, and operating EPS up 14%. Raised full-year 2026 guidance for operating EBITDA ($4.1B-$4.3B), margin (22.5%-23.5%), and EPS ($3.60-$3.80). Seed business saw organic sales growth across all regions, driven by technology adoption and licensing income. Crop protection new products achieved high single-digit volume growth, with pricing essentially flat for these products. Productivity initiatives and cost discipline contributed over $160 million to EBITDA in the first half. Separation on track for October 1, with synergies largely offsetting separation costs (only $25M headwind). Strong innovation pipeline with seven new crop protection actives expected over the next decade.

Negative Points

Crop protection pricing remains under pressure, particularly in Latin America, with expectations of low to mid-single-digit declines in the second half. Brazilian farmer credit conditions are tight, potentially impacting order timing and demand. Second-half EBITDA expected to be flat year-over-year due to tariffs, dissynergies, and Middle East conflict impacts. Third quarter expected to see an operating EBITDA loss, with earnings heavily weighted to Q4. Full-year free cash flow impacted by one-time items (pension contribution, Bayer agreement, separation costs). Competitive pressure in crop protection, especially for off-patent products, requires ongoing cost reductions to maintain margins. Weather-related risks (e.g., El Nino) could reduce fungicide demand in certain regions.

Q & A Highlights

Warning! GuruFocus has detected 7 Warning Signs with ARES. Is CTVA fairly valued? Test your thesis with our free DCF calculator.

Q: Can you discuss the second-half outlook for the seed business, particularly regarding flat corn acre assumptions, order books, and pricing/mix expectations for Conkesta penetration?A: Jud O'Connor, EVP, Seed Business Unit: For the second half, the focus is on Latin America, especially Brazil. While we've seen low single-digit Safrinha expansion for several years, we could see it flatten in 2027. Our order book is ahead of the market, and we feel confident in our product portfolio and strong pricing in Latin America. For Conkesta, we expect high single-digit to low double-digit penetration in 2027, and we remain very optimistic about its performance.

Story Continues

Q: As the incoming CEO of New Corteva, what are you most excited about regarding the company's narrative, portfolio, and pipeline?A: Luke Kassam, Future CEO, New Corteva: The number one strength is our people, many of whom understand farmer challenges firsthand. Two-thirds of our portfolio is differentiated technology, and we aren't dependent on any single active, segment, crop, or geography. Adding biologicals allows us to blend natural and synthetic solutions. Our pipeline is the best in crop protection, with seven new actives coming to market over the next decade. I'm incredibly excited about the R&D results we're seeing in our greenhouses and look forward to sharing more at our Investor Day on September 15th.

Q: Given your prior 2027 guidance of $4.4 billion EBITDA, you're now at $4.2 billion midpoint for 2026. Is mid-single-digit growth into next year still the right way to think about it?A: Chuck Magro, CEO: Not much has changed from our original thinking. The updated guide of $4.2 billion fits comfortably into our 2027 target of $4.4 billion. We're actually a little ahead of our original plan for 2026, driven by core parts of the business. Licensing is three years ahead of plan, and crop protection new products will touch $2 billion in revenue this year with strong margins. David Johnson, CFO, added that the $4.4 billion target remains comfortable, and we're tracking flat on net dissynergies and separation costs.

Q: Can you unpack the underlying sales trends in crop protection, given organic sales were down 6% but the "other" category grew substantially? What trajectory should we expect?A: Chuck Magro, CEO: The overall crop protection market is improving, with low single-digit growth expected this year. We're seeing volume growth with low single-digit pricing declines, as expected. There's more competitive pressure in Brazil, but nothing outside our planning horizon. Chinese exports are stable. We've proactively managed our cost structure for products coming off patent, which has allowed us to maintain margins. Looking forward, we have seven new actives coming, starting with Haviza, a blockbuster fungicide for Brazil in the next couple of years.

Q: Did you gain share in North American corn or soybeans this growing season?A: Jud O'Connor, EVP, Seed Business Unit: We feel confident we picked up a little share in corn, particularly with our retail brand and in Brabant, despite our premium price/value strategy. In soy, we gained share in both the Western and Eastern Corn Belt with the Pioneer brand, but gave up a little in the Delta due to dicamba label challenges with cotton. Overall, we expect to end up flat in soy and with a slight share gain in corn.

Q: Given that two-thirds of the crop protection portfolio is differentiated, why is pricing still declining low to mid-single-digits? Can you parse out the differentiated side?A: Chuck Magro, CEO: In the first half, pricing was down about 3%, within expectations. Europe and the US were essentially flat. Our new products, approaching $2 billion in revenue, have flat pricing with high single-digit volume growth. The pressure is coming from the rest of the market, particularly in Brazil and pre-emergent herbicides. We've moved second-half pricing expectations from low single-digit to mid-single-digit declines, driven by Brazil and weather impacts on fungicide demand. However, we still expect to grow EBITDA, led by volume.

Q: Can you parse out the price versus volume in Seed for the second half, and should we think about transitioning to a combined organic view?A: Jud O'Connor, EVP, Seed Business Unit: The second half is a much smaller part of our seed business, focused on Brazil. We forecast volume to be relatively flat year-over-year as we don't expect as big an expansion in Safrinha planted area. Price/mix will be driven by bringing new products to market, allowing us to share in the additional value. David Johnson, CFO, added that the second half is about 27% of total top-line, and we project a 50/50 split between price and volume gains.

Q: Where do your Brazil order books stand versus historical trends, and what are the drivers?A: Jud O'Connor, EVP, Seed Business Unit: We are ahead of the market in terms of overall orders, so we feel great about our competitive position. However, growers are making decisions closer to planting time due to tight credit and stress on margins from fuel and fertilizer prices. We feel confident in our order book, share position, and product portfolio, which is as good as it's ever been in Brazil for both summer and Safrinha crops. We'll need to manage alongside the tight credit conditions.

Q: Can you expand on the timing shift between Q3 and Q4, given the implied Q4 EBITDA growth?A: David Johnson, CFO: Our second-half guide is flat versus 2025 at around $500 million, which was a strong half (up 16% versus 2024). We have some unfavorable price and cost built in, including the residual $25 million synergy impact and logistics costs, offset by volume and favorable currency. The second half is about 12% of our full-year guide, in line with the past four years. The Q3 loss will likely be around $100 million, more typical of a couple of years ago, with some additional costs like net dissynergies weighted to Q3.

Q: Where are the big advantages for incremental productivity savings between Violor and New Corteva on a separate basis?A: David Johnson, CFO: In our last three-year guide, we had about $1 billion of growth productivity cost benefits.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

View Comments